Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data & AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma & Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
Subscribe
Subscribe

False

The Analytical Scientist / Issues / 2020 / Apr / Mapping Melanoma
Chromatography Liquid Chromatography Omics Proteomics Clinical

Mapping Melanoma

LC-PRM-driven proteomics helps explore the mechanisms behind cancer metastasis

By Matt Hallam 04/16/2020 1 min read

Share

Targeted quantitative proteomics – using LC-parallel reaction monitoring (PRM) – is shining a light on kinome protein reprogramming during melanoma metastasis. Weili Miao and colleagues found that the expression of Janus kinase 3 (JAK3; a tyrosine kinase) is reduced in metastatic melanoma cells when compared with primary (non-metastatic) cells, by applying LC-MS and LC-MS/MS to tryptic digests.

Targeted quantitative proteomics – using LC-parallel reaction monitoring (PRM) – is shining a light on kinome protein reprogramming during melanoma metastasis. Weili Miao and colleagues found that the expression of Janus kinase 3 (JAK3; a tyrosine kinase) is reduced in metastatic melanoma cells when compared with primary (non-metastatic) cells, by applying LC-MS and LC-MS/MS to tryptic digests. Reduced JAK3 is associated with poorer melanoma prognosis because it inhibits the activity of matrix metalloproteinases – key enzymes involved in the metastatic transition.

The gathered data represent the most comprehensive available for these proteins in melanoma metastasis, and the knowledge inferred by such data could inform future drug discovery efforts.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. W Miao et al., Sci Rep, 10, 2485 (2020). DOI: 10.1038/s41598-020-59572-5

About the Author(s)

Matt Hallam

I've always wanted a job that fosters creativity - even when I worked on the assembly line in a fish factory. Outside work, I satisfy this need by writing questionable fiction. The venture into science writing was an unexpected departure from this fiction, but I'm truly grateful for the opportunity to combine my creative side with my scientific mind as Editor of The Analytical Scientist.

More Articles by Matt Hallam

False

Advertisement

Recommended

False

False

The Analytical Scientist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.